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ABSTRACT
Young women bear a disproportionately high burden of HIV infection in sub-Saharan Africa,
prioritising pre-exposure prophylaxis (PrEP) can be an integral part of HIV prevention
combination strategies. Women initiated HIV prevention technology options will require
consistent adherence, an imperative for product effectiveness. With several PrEP clinical trials
underway; exploring women’s acceptability to advances in HIV prevention technologies can
better facilitate demand creation for future PrEP roll out. This study utilised the opportunity of
post-trial access to CAPRISA 008 women (trial) and non-trial women from three geo-spatial
settings (urban, rural and peri-urban) to identify microbicide acceptability and how product
associations of microbicides can influence future HIV prevention choices. Six participatory
workshops using participatory action research with art-based activities and discussion groups
were conducted in KwaZulu-Natal with 104 women from various geo-spatial locations and social
status to understand microbicide acceptability and product associations. The data were analysed
using thematic analysis. The study found that women’s acceptability and product association of
the tenofovir gel microbicide differed according to rural and urban areas. Most urban women
identified confidence, sexiness and classiness as key associations that will encourage microbicide
acceptability and use, while rural women identified respect, responsibility and confidence as the
key product associations, with increased focus on the individual and collective family/community
benefits of product acceptance and use. Urban–rural differences suggest a market segmentation
that is contextualised to be locally responsive to promote HIV prevention technologies. Various
sexual encounters further determined the types of HIV prevention technologies women would
consider. In line with WHO’s recommendation that PrEP should be an additional prevention
choice for people at risk of HIV, this study underscores the importance of user engagement,
understanding product associations and how this can influence product acceptability and
promotion of HIV prevention technologies.
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HIV incidence rates have slowed down globally, yet sub-
Saharan Africa still has one of the highest rates of new
HIV infections (UNAIDS, 2015). Although the epidemic
affects both men and women, 60% of new infections in
South Africa occurs among young women (Shisana
et al., 2014). South Africa has one of the highest numbers
of HIV infections, (UNAIDS, 2014) with the highest HIV
prevalence rates in KwaZulu-Natal. Young women (aged
15–24 years) bear a disproportionate burden of HIV
infection, having up to eight times more infection com-
pared to their male peers (Dellar, Dlamini, & Abdool
Karim, 2015), and acquire HIV infection at least five to
seven years earlier than men (UNAIDS, 2014). In the
age group 15–49 years, prevalence of HIV amongst
female was 23, 3% and 13, 3% among South African
males (Shisana et al., 2014), indicating that women
need more sustainable HIV prevention options. With
limited safe and effective women-centred HIV preven-
tion options, progress on pre-exposure prophylaxis
(PrEP) has the potential to reduce transmission of HIV.
Since 2010, the outcomes of several trials have
demonstrated the prevention benefit of the prophylactic
use of antiretrovirals that has generated new hope in pre-
venting sexually acquired HIV infection. Several studies
of daily and intermittent dosing strategies in different
settings, populations and modes of transmission have
confirmed the prevention benefits of tenofovir-based
products in HIV-uninfected persons (Abdool Karim
et al., 2010; Baeten et al., 2012; Cohen et al., 2011;
Grant et al., 2010; McCormack et al., 2016; Molina
et al., 2015; Thigpen et al., 2012). For the first time, the
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most recent WHO ARV Guidelines released in Septem-
ber 2015 makes a strong recommendation for the pro-
vision of tenofovir-containing PrEP to be offered as an
additional prevention choice for people at substantial
risk of HIV infection as part of combination HIV pre-
vention approaches (WHO, 2015).
An expanding HIV PrEP pipeline with several inno-
vations under clinical trial will result in women having
a buffet of HIV preventative options. As product devel-
opment, formulations and dosing strategies/options
expand, and as evidence of efficacious prevention pro-
ducts emerge, there is an urgent need for an in-depth
understanding of what influences product acceptability.
Studies focusing on microbicides in the form of vaginal
gels and rings, which have already undergone clinical
trials, can provide critical information about potential
users’ product perceptions which can influence microbi-
cide acceptability. Microbicides are likely to be part of a
comprehensive HIV prevention strategy in the future,
existing research on microbicides suggest that there is a
need to investigate factors that may contribute to the
acceptance, uptake and adherence of microbicides as HIV
prevention technologies (Kelly et al., 2015; Kippax, 2012;
MacQueen et al., 2014), with a specific focus on the accept-
ability of microbicides in a cross-cultural context (Greene
et al., 2010; Mantell et al., 2005). This study utilised the
opportunity to work with CAPRISA 008 post-trial partici-
pants (rural and urban) and extended to women who have
not participated in clinical trials (rural, peri-urban and
urban) to explore their acceptability of microbicides and
specific product associations that can influence the future
uptake of HIV prevention technologies. The mix of trial
and non-trial women was to ascertain product associations
from women who used the gel previously and those who
were introduced to the gel for the first time.
Methods
The intervention
This study used participatory action research (PAR) as a
process of engaging women in ongoing dialogue to under-
stand often complex, multi-dimensional, intractable and
dynamic problems (Brydon-Miller, 2003; Brydon-Miller,
Greenwood, & Maguire, 2003, p. 21), such as acceptability
of microbicide use. The PAR process engaged women in a
collective and cyclical process of discussionwithin the con-
text of female-initiated HIV prevention options. PAR pro-
vides a way for women to take part in “the process of
generating knowledge and advocating positive social
change in order topromotemore effective health care prac-
tices” (Brydon-Miller, 2003, p. 187). The women attending
the workshops were provided with large sheets of paper,
and through a facilitated process, asked to write, draw or
discuss their ideas about their own associationswith poten-
tial microbicide use. A brief background to HIV preven-
tion, the need for more comprehensive HIV prevention
options for women, the advancement of clinical trials and
the introduction to vaginal microbicides and dosing strat-
egies informed the introduction to microbicides using
visual aids. The workshops were conducted in English
with isiZulu translations where necessary for clarification.
The womenwere provided with a range of oil pastels, mar-
kers and coloured paper and given 60 minutes to work in
groups of 3 or 4 women to collectively document and dis-
cuss their product association with potential microbicide
use. The documented artwork was not analysed but used
as a catalyst to initiate a knowledge sharingprocess through
group discussions. After smaller group engagement and
reflection, bigger discussion groups were convened. These
were facilitated by the first author with assistance from a
bi-lingual facilitator. In line with PAR techniques, journal
notes were taken of observations, with auto recording of
discussions. The discussions were transcribed and the
text analysed using thematic analysis to establish the key
product associations that can influence microbicide
acceptability.
Sampling
Convenience sampling was used to recruit women to
attend these workshops, with the key eligibility criteria
that all women had to be over 18 years of age. Whilst
HIV negative status is a determinant for future eligibility
for microbicide use, knowledge of HIV status was not a
requirement for sampling. DramAidE (Drama in AIDS
Education), a non-governmental organisation facilitated
the recruitment of non-trial women in eThekwini
(urban) and Umnini (peri-urban), with COMOSAT
(Community Outreach Programme in Vulindela) assist-
ing with recruitment of non-trial women in Vulindela
(rural). Women who participated in the tenofovir gel
clinical trial were asked to volunteer to have their contact
details shared with the researcher, and if they agreed their
permission was documented in their trial records. A ran-
dom selection of trial participants were contacted for par-
ticipation in this study. The inclusion of trial women
contributed to the discussion of product associations
from women who were exposed to the gel use and those
who were introduced to the gel for the first time. Trial
women were specifically included in the study not for
comparative analysis but as good PAR practice (McIntyre,
2009), to ensure that they were not only part of the clinical
trial phase but also contributed to understanding microbi-
cide acceptability. The researcher anticipated that through
the inclusion of trial participants without a direct
AIDS CARE 735
disclosure of their involvement, it will provide a space for
inclusion of their perspectives of microbicide acceptability
and product associations. Informed consent was obtained
from all trial and non-trial women. Ethical clearance was
obtained from the Human and Social Science Ethics Com-
mittee of the University of KwaZulu-Natal, South Africa.
Workshop composition
Women were recruited from three geo-spatial locations
(urban, peri-urban and rural) for a diverse represen-
tation of potential microbicide users. Trial and non-
trial women were included in this study, with trial
women being those who had used the tenofovir gel in
a clinical trial and non-trial women are those who have
not used the gel or enrolled into any clinical trials under-
way. Participants were briefed that the product is a clini-
cal trial product, and can reduce HIV infection by up to
39% if adhered to consistently (Abdool Karim et al.,
2010). They were also briefed on the benefits of gel
use, the application process and the need to still consider
other HIV preventative measures. All participants were
informed that the product was not available at the time
of the study, but the purpose is to get an in-depth under-
standing of their acceptability.
A total of 6 workshops were conducted with conven-
ience sampling of 20 women for each of the workshops.
Not all of the women recruited attended; hence each
workshop had a varying number of women in attendance
(see Table 1). The eThekwini mixed group had increased
numbers due to participants self-inviting other women
interested in the study, given the PAR methodology of
the study, these additional women were not denied par-
ticipation in the study. Two of the six workshops were
conducted with mixed groups of trial and non-trial
women in urban (eThekwini) and rural (Vulindela) set-
tings, as these were the sites for the CAPRISA008
implementation study. Mixed groups of trial and non-
trial women from the various geo-spatial locations were
used to ensure that the confidentiality of the trial
women was still maintained when working with the facil-
itators: facilitators were unaware of whowere the trial and
non-trial women. Four of the six workshops were con-
ducted with non-trial women only in a rural (Vulindela),
peri-urban (Umnini) and two urban sites (eThekwini).
The two urban sites purposively selected two varying
groups of women; a student group between the ages of
18–24 years, and a working professionals group between
ages of 25–49 years to understand the microbicide
acceptability and product associations of women from
various ages and social status. Women selected from
urban, rural and peri-urban locations and from varying
age groups and social status catered for a more nuanced
understanding of microbicide acceptability and its influ-
ence on future product uptake.
The data presented below are the key themes from the
data analysed highlighting the influence geo-spatial
locations and varying types of sexual encounters onmicro-
bicide acceptability. Thematic analysis was conducted
where repetition of common issues were identified as the
central themes for discussion. The broader themes were
refined into specific codes with two coders reading the
text to identify common themes and codes. The codes
were compared periodically to ensure that the codes were
similar.
Overall the study was limited in understanding the
actual trial participant acceptability of microbicides as
the focus groups were not constituted to offer this com-
parative data of clinical trial users and potential users, in
addition further research that extends to more sites of
urban and rural locations can enhance understanding
on potential microbicide acceptability.
Results
Confident women use microbicides
Microbicide use was accepted as a female-initiated pre-
vention option with many associating that only
Table 1. Breakdown of workshop sample.
Geo-spatial location Trial/non-trial women Age Social status (occupation) Total in attendance




Stay at home moms, domestic workers and un-
employed
14




Stay at home moms, domestic workers/cleaners
and admin jobs/un-employed
31
Umnini (peri-urban) Non-trial women 18–55
years
Stay at home moms, domestics, part time
students and un-employed
16
Vulindela (rural) Non-trial women 18–55
years
Stay at home moms, domestic workers and un-
employed
10
eThekwini (urban students) Non-trial women 18–24
years







Professional working women 17
104 women (45 mixed group women
and 59 non-trial women)
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“confident women” would use the product. A “confident
woman” was described as someone who understands the
importance of protecting herself, and is able to take the
relevant steps to ensure she adheres to the product.
The terms “confident” were commonly associated
with women who accept microbicide use, however
women in the urban and rural areas ascribed subtly
different meanings to the term confident. The urban
women’s notion of a confident woman was associated
with “sexiness”: the use of vaginal microbicides suggested
a feeling of sexiness and confidence by lowering the risk
of HIV infection. Urban women directly related potential
microbicide use to women feel sexier and hence more
confident about sex, where confidence was used to
describe microbicide use as empowering and taking
responsibility for an individual’s sexual well-being. Sexi-
ness was defined for urban women as feeling more phys-
ically appealing when having the freedom and
confidence to prevent HIV infection.
The rural women on the other hand, associated
microbicide use with “confidence” and “respect” where
“respect” signified the individual and collective responsi-
bility of reducing the risk of HIV infection. The accept-
ability of microbicides in rural areas suggested that
women were collectively taking steps to protect them-
selves, making them confident about their responsible
sexual choices. The rural women’s confidence was
associated with an individual agency of protection, yet
in considering microbicide use rural women are
respected for protecting themselves and their family,
extending microbicide acceptability to a wider collective
community benefit. The use of the term “confidence”
was strongly advocated for both mixed groups in urban
and rural settings, suggesting that some women could
have responded from their position of actual product
use.
Location determines microbicide use
Women from all locations believed that the gel was an
opportunity to protect themselves in the absence of con-
dom negotiation, increase of sexual assault and domestic
violence, partner unfaithfulness and male dominance.
Women in rural areas were more likely to use microbi-
cides as many knew when they will see their partners,
or when they are returning home from long periods of
work – gel application was identified as an easy process
in these instances. Urban student’s acceptance and
potential for product uptake differed depending on the
campus residential and non-residential living arrange-
ments; those who lived at home with parents identified
the need to secretly store the gel as a deterrent of product
use. Those living at campus/university residence had
more freedom with HIV prevention product choices.
The working urban women identified that many who
were in long-term relationships may not require the gel
use, unless they suspected partners unfaithful. The
peri-urban women’s uptake of microbicides were linked
to the long distance many young girls had to walk to
school, and their increased exposed to risk through
opportunities for transactional sex and cases of rape.
Overall the rural women’s acceptability of microbi-
cides was associated with the women’s ability to feel
proud of her step towards reducing risk of HIV infection.
While many identified the importance of the product
empowering women to prevent HIV in cases where
men were unwilling to use the condom, rural women
had a greater acceptability for microbicide use when
men were supportive of their HIV prevention choices.
For most rural women, acceptability of microbicides
was empowering for women but male support of
female-initiated prevention reaffirmed the importance
of trust, openness and the willingness to talk about
microbicide use to their family and friends.
This was contradictory for urban women where
microbicides had increased acceptability due to covert
use. Urban women identified an increased receptivity
to microbicide use due to the discreet application,
whereas HIV prevention product visibility (i.e., female
condoms) would pose issues of trust and assumptions
of unfaithfulness if used in long-term relationships.
While both groups of rural and urban women identified
that microbicide acceptability was linked to women feel-
ing empowered and having agency to take individual
responsibility, the urban–rural contrast of understanding
this agency suggested that male support of female-
initiated prevention would increase microbicide accept-
ability in rural locations, while urban women were in
favour of product privacy and secrecy of microbicide use.
Varying sexual encounters influence microbicide
acceptability
The rural and peri-urban women were less prescriptive
in who the specific target group of women should be
for microbicide use in the future. Instead they strongly
advocated that microbicides should be used by all sexu-
ally active women.
The urban women identified that microbicides in the
form of gel was not for all sexually active women. The
urban lifestyle was described as being very different to
rural settings: seeing partners more regularly, living
with their partner and having a more spontaneous social
life meant that gel use varied according to urban life-
styles. The working class women in particular identified
that living with or seeing their partners spontaneously
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made the dosing strategy less appealing as sex is not
always a rational activity. However, the gel could work
for women in stable relationships but were aware of
their partner/husband’s closet (secretive) relationships
and needed a discreet way to still be able to protect them-
selves. The urban students compared the varying life-
styles of living with parents, living alone and studying
away from home as a key variable in microbicide accept-
ability and future uptake. Many discussed the complex-
ities of storing the gel if residing with parents, as
opposed to living in university residence. Students
found that the gel’s dosing strategy was less appealing
for them, giving the often-impromptu nature of their
sexual engagement. Many suggested that microbicide
uptake must consider these types of varying sexual
relationships and ever changing sexual landscapes. Over-
all, urban women lifestyles and residential variances
influenced the acceptability of gel microbicide use.
Tenofovir gel acceptability had considerable merit in
cases where women were knowledgeable about when
they were likely to have sex. Many urban women
suggested that the gel would work well in cases of
planned and scheduled sexual encounters as long as
the product was consistently adhered too. Transactional
sex, women in relationships with migrant workers,
“sugar daddy” relationships and cases of where sex is a
planned encounter, would be favourable opportunities
for the consistent and correct application of the gel.
Most urban women (students and working professionals
only) argued that the BAT24 dosing strategy (up to 12
hours before sex, and up to 12 hours after sex) created
several product limitations, as most sexual encounters
were unplanned and spontaneous. The routine appli-
cation of the gel negatively influenced consistent adher-
ence. Women from peri-urban and rural locations on the
other hand, had a better indication of when they would
see their partners or when they were likely to return
home from jobs in the city. The gel, if adhered to consist-
ently, could work well in cases of planned and rational
sexual encounters. Given the BAT24 dosing strategy,
women who engage in scheduled or routine sex would
mostly benefit from the product.
Discussion
Understanding who are the potential microbicide users
and the receptivity of female-initiated HIV prevention
offers critical information to advance PrEP product
development and implementation. The data above high-
light a distinct urban–rural disparity on microbicide
acceptability for reducing the risk of HIV infection.
The data collected in KwaZulu-Natal across rural, peri-
urban and urban settings clearly suggest that the dosing
strategy works only for specific planned sexual encoun-
ters and hence creates a market segmentation among
women in terms of HIV preventative measures. Geo-
spatial contexts are important as women’s preventative
preferences can be influenced by the type of sexual
relationships and where they reside, and underscores
the importance of participatory research to inform and
match new biological products with the right cohort of
potential women and users. Future HIV prevention tech-
nologies will need to prioritise an understanding of the
potential users, their patterns of various sexual beha-
viours in various locations and the predictors of product
acceptability to encourage instant adoption of female-
initiated prevention once available (see McMahon,
Myers & Kurth, 2014; Young & McDaid, 2014).
Extrapolating from this research, we can apply the
results of this study to think about how to promote pro-
duct acceptability for PrEP products still undergoing
clinical trial. The research highlights the importance of
conducting ongoing research to understand the match
between what will influence acceptability of HIV preven-
tion technologies and how best to position PrEP for
future demand. Studies conducted on microbicide use
in Kenya further highlighted the importance of tailored
microbicide communication materials for women who
do not use HIV prevention methods and those who
have a high-risk perception (Ryan et al., 2015; Sidibe
et al., 2014). The HIV pandemic from inception has
demonstrated the complexities of human behaviour, and
the multiple biological, social, economic, cultural and
environmental factors that need to be considered when
trying to promote behaviour change (Dutta, 2008, 2011,
2013). These biomedical options for women are a first
step and opportunity to customise HIV risk reduction
strategy with specific sexual behaviours and practices.
While PrEP options such as the vaginal microbicide can
promote HIV prevention and be a tool for empower-
ment of women, a context-specific approach is necessary
to understand how women define confidence, respect,
responsibility and empowerment.
With several clinical trials underway, women may for
the first time in three decades have a variety of options to
select the most context-specific HIV prevention technol-
ogies, which can be available in a variety of formulations
and delivery mechanisms (Celum et al., 2015). Notwith-
standing that they are in different stages of development
they enable a different approach to introduction and
evaluation of each option: this allows better matching
of product with what women need in different epidemic
settings linked to perception of risk; nature and timing of
coital encounters; and other needs, desires and prefer-
ences that women have or need from HIV prevention
technologies.
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Conclusion
The findings of this study overall suggest that acceptabil-
ity of microbicides are significantly influenced by under-
standing the localised and cultural context in which
women make sense of female-initiated HIV prevention
methods. Understanding the product associations of
the women according to geo-spatial locations and types
of sexual encounters can better position PrEP for future
demand creation.
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